Fresenius Medical Care released its 2024 Annual Report, including its Sustainability Statement, titled 'Building the Momentum.' The report summarizes the company's financial, social, and ecological developments over the past year, emphasizing dynamic earnings and margin growth.
The report highlighted key achievements for 2024, including 4% organic revenue growth and 18% operating income growth on an outlook base. The company also noted its success in lowering debt, raising the dividend, and positioning itself for a new level of earnings growth in 2025.
Additionally, the Annual Report detailed progress in sustainability, with a global patient Net Promoter Score (NPS) of 72 and a 25% reduction in Scope 1 and Scope 2 emissions compared to 2020. It also mentioned the 510(k) clearance for the 5008X machine from the U.S. Food and Drug Administration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.